Union health minister Harsh Vardhan has said that all the people who will receive Bharat Biotech’s vaccine Covaxin will be tracked and monitored like in trials.
“For those spreading rumours let it be known that emergency use authorization (EUA) for Covaxin is differently conditional in clinical trial mode,” Harsh Vardhan tweeted.
“EUA for Covaxin is different from Covishield because its use will be in clinical trial mode. All Covaxin recipients to be tracked, monitored as if they’re in trial,” he added.
The minister further said that Covaxin’s approval was ‘monitored approval’ with strict follow-up and rolling review.
“This approval ensures India has an additional vaccine shield in its arsenal, especially against potential mutant strains in a dynamic pandemic situation. It is a strategic decision for our vaccine security,” the minister said.
Hitting back at those doubting the vaccine approvals, Harsh Vardhan said that the World Health Organization has welcomed the Indian approval of both Covishield and Covaxin.
“Kudos to Hon’blePM Narendra Modi for re-establishing India as the vaccine capital of the world! Anti-national comments & cynicism of the Opposition notwithstanding, WHO has welcomed the Indian approval of both Covidshield and Covaxin! Roll up your sleeves everyone!” he tweeted
“The whole world is cheering India for granting emergency approval to Serum Institute of India and Bharat Biotech vaccines ensuring safety, efficacy & immunogenicity showcasing our scientific capability & innovation ecosystem. India celebrates the win but Opposition fails to applaud our prowess,” the minister tweeted further.